GLENMARK PHARMA: Q2 CONS NET PROFIT 6.1B RUPEES VS 3.54B (YOY) || Q2 REVENUE 60.5B RUPEES VS 34B (YOY) Q2 EBITDA 23.6B RUPEES VS 6.1B (YOY) || Q2 EBITDA MARGIN 39.03% VS 17.88% (YOY) Blastttttt